Liraglutide for non-alcoholic fatty liver disease in children and adolescents: has a new era arrived?
Main Author: | Dimitrios Patoulias |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2019-09-01
|
Series: | Gastroenterology Review |
Online Access: | https://www.termedia.pl/Liraglutide-for-non-alcoholic-fatty-liver-disease-in-children-and-adolescents-has-a-new-era-arrived-,41,37806,1,1.html |
Similar Items
-
Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?
by: Dimitrios Patoulias, et al.
Published: (2020-10-01) -
Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes,
and cardiovascular disease
by: Dimitrios Patoulias, et al.
Published: (2018-12-01) -
Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System
by: Mengying Yang, et al.
Published: (2020-04-01) -
Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways
by: Luo Y, et al.
Published: (2019-12-01) -
Determining whether the effect of liraglutide on non‐alcoholic fatty liver disease depends on reductions in the body mass index
by: Megumi Shiomi, et al.
Published: (2020-10-01)